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were	 asked	 to	 refer	 to	 the	Department	potentially	 eligible	 infants	
and	to	provide	support	to	the	parents	of	those	eventually	enrolled	





The	 study	 protocol,	 the	 subject	 information	 sheet	 and	 the	 in‐
formed	 consent	 form	were	 reviewed	 and	 approved	 by	 the	 ethics	
committee	of	our	institution.
The	study	was	conducted	in	accordance	with	the	Good	Clinical	
Practice	 Standards	 and	 study	 monitoring	 was	 performed	 by	 the	





Otherwise	 healthy	 exclusively	 breastfed	 infants	 aged	 ≤7	 weeks,	
with	signs	and	symptoms	possibly	related	to	IC	according	to	Rome	
III	Criteria,10	regularly	followed	by	the	family	paediatricians	involved	





The	 exclusion	 criteria	 were	 the	 following:	 age	 ≥7	 weeks,	 birth	
weight	<2500	g,	gestational	age	<37	weeks,	Apgar	score	at	5	min‐
utes	 <7,	 partially	 or	 total	 formula	 feeding,	 stunted	 growth/weight	
loss	 (<100	g/week	from	birth	to	 last	 reported	weight),	neurological	
diseases,	suspected	or	confirmed	food	allergy,	gastroesophageal	re‐
flux	disease,	use	of	probiotics,	prebiotics,	antibiotics	or	gastric	acid‐
ity	 inhibitors	at	any	time	before	enrolment,	 fever	and/or	 infectious	
diseases	at	any	time	before	enrolment,	current	systemic	 infections,	
history	 of	 congenital	 infections,	 chronic	 intestinal	 diseases,	 cystic	
fibrosis	 or	 other	 forms	 of	 primary	 pancreatic	 insufficiency,	 gastro‐
intestinal	 malformations,	 metabolic	 diseases,	 genetic	 diseases	 and	










and	 clinical	 examination,	 including	 vital	 signs,	 neurological	 status,	
growth	 status,	 nutritional	 status,	 hydration,	 skin	 evaluation,	 otos‐
copy,	 evaluation	 of	 oral	 cavity,	 respiratory/abdomen/lymphnode	
examination	 and	 genital	 examination.	 Anamnestic,	 demographic,	
anthropometric and clinical data were collected and reported in a 
specific	clinical	chart.
Then,	 infants	were	 required	 to	 follow	a	1‐week	pre‐enrolment	
period.	 If	 after	 this	 period	 the	diagnosis	 of	 IC	was	 confirmed,	 the	
subject	was	randomised	to	one	of	the	following	study	groups:	Group	
1,	parental	 reassurance	and	education	plus	BB‐12	 (Bifidobacterium 





six	 drops	 of	 the	 assigned	 study	 product,	 once	 a	 day,	 for	 28	 days	
directly	 in	 the	 mouth,	 preferably	 in	 the	 morning	 before	 feeding.	
Instructions	for	keeping	and	maintaining	the	product	were	also	pro‐
vided	according	 to	 the	manufacturer’s	 indications.	Study	products	
were	 provided	 by	 Sofar	 SpA.	 The	 patient's	 parents,	 investigator	
staff,	persons	performing	the	assessments	and	data	analysts	were	




The	 bottles	 containing	 the	 probiotic	 or	 the	 placebo	were	 labelled	

























At	each	visit,	 the	parents	of	 the	patients	were	asked	to	 report	




































Active product, 6 drops/day (109 CFU) (and restriction of prebiotics, probiotics, synbiotics and anticolics)
Placebo, 6 drops/day (and restriction of prebiotics, probiotics, synbiotics and anticolics)
*randomisation was performed according to as randomisation scheme without reference to group assignment








V1 = Day 7
Evaluation visits
Coordinator Center
V2 = Day 14 V3 = Day 21 V4 = Day 28
Final visit
Coordinator Center
V5 = Day 35
(A)
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2.3 | Study outcomes
The	 primary	 outcome	 of	 the	 study	was	 the	 proportion	 of	 infants	
with	 a	 treatment	 success	 rate,	 defined	 as	 a	 reduction	of	 ≥50%	of	
mean	daily	crying	duration	after	28	days	of	intervention.
The	 secondary	 outcomes	 were:	 the	 mean	 number	 of	 crying	
episodes;	 sleep	 duration;	 number	 of	 bowel	 movements	 and	 stool	
consistency.	 Study	 groups	were	 also	 compared	 for	 gut	microbiota	
structure,	 faecal	 levels	 of	 human	 beta‐defensin	 2	 (HBD‐2),	 cathe‐




Human	 beta‐defensin	 2,	 LL‐37	 and	 sIgA	were	measured	 from	 the	
supernatants	of	faecal	homogenates,	using	commercial	kits	as	pre‐
viously	described.12	HBD‐2	was	measured	using	a	HBD‐2	(Human)	
ELISA	 kit	 (Phoenix	 Pharmaceuticals,	 Inc),	 LL‐37	 using	 an	 ELISA	
human	 kit	 (Hycult	 biotechnology)	 and	 sIgA	 using	 indirect	 enzyme	
immunoassay	(Salimetrics	LLC).	The	results	were	expressed	as	ng/g	
for	HBD‐2,	LL‐37	and	as	μg/g	of	supernatant	for	sIgA.
Faecal	 calprotectin	 level	 was	 determined	 using	 a	 commercial	
ELISA	 kit	 (Calprest,	 Eurospital)	 as	 previously	 described,13 and the 
result	was	expressed	as	mg/Kg	of	faeces.
Figure 3 . Assessed for eligibility (n = 80)
Analysed in ITT analysis (n = 40)
Analysed in PP analysis (n = 40)
Lost to follow-up (give reasons) (n = 0)
Discontinued intervention (n = 5: adverse 
event = 1, non compliance of family = 2, difficulty 
in completing diary = 2)
Allocated to BB12 (n = 40) 
Received allocated intervention (n = 40)
Did not receive allocated intervention (n = 0)
Lost to follow-up (give reasons) (n = 0)
Discontinued intervention (n = 3: non
compliance of family = 2, difficulty in completing
diary = 1)
Allocated to placebo (n = 40)
Received allocated intervention (n = 40) 
Did not receive allocated intervention (n = 0)
Analysed in ITT analysis (n = 40) 




Randomized (n = 80)
Enrollment
Panel (B)
F I G U R E  1   (Continued)





preparation,	 sequencing	 and	data	 analysis	were	 carried	out	 as	 re‐
cently	described.15	Briefly,	raw	reads	were	joined	using	FLASH16 and 
quality‐filtered	by	Prinseq,17	 trimming	out	bases	with	Phred	 score	
























for	 dichotomous	 variables.	 Percentages	were	 computed	 consid‐











analyses	 of	 the	 secondary	 outcomes	 were	 performed	 on	 the	 ITT	
population	only.	 The	 safety	 analysis	was	performed	on	 the	 safety	
set	population.
Mean	 daily	 crying	 duration,	 the	 mean	 number	 of	 daily	 crying	
episodes,	 the	mean	 daily	 duration	 of	 sleep	 (in	minutes)	 and	 stool	
frequency	were	described	 for	 each	week	by	means	of	 descriptive	
statistics	 for	 continuous	 data	 and	 were	 calculated	 on	 nonmissing	



































































Safety	 data	 were	 summarised	 by	 treatment	 on	 the	 Safety	 set	
population.	The	incidence	of	Adverse	Events	during	the	study	was	












following	variables:	duration	of	 crying,	LL‐37,	 sIgA,	 faecal	butyr‐
ate,	 calprotectin	 and	 HBD‐2.	 Nonparametric	 Kruskal‐Wallis	 and	
pairwise	Wilcoxon	 tests	were	carried	out	 in	order	 to	 find	differ‐
ences	 in	microbial	 taxa,	butyrate	or	 immunity	peptides	between	
placebo	 and	 BB‐12	 or	 between	 responders	 and	 nonresponders.	
All	p‐values	were	corrected	for	multiple‐comparison	testing	when	
appropriate.20






The	 flow	of	 the	 subjects	during	 the	 study	 is	 reported	 in	Figure	1,	
panel	b.	Eighty	infants	were	enrolled	and	randomised,	40	per	group;	
eight	 subjects	 did	 not	 complete	 the	 study	 due	 to	 noncompliance	
of	 the	family	 (n	=	3),	difficulty	 in	completing	the	diary	 (n	=	3),	 lost	
to	follow‐up	(n	=	1)	or	adverse	event	(n	=	1).	Seventy‐two	subjects	
completed	the	study:	35	 in	BB‐12	group	and	37	 in	placebo	group.	
All	 infants	 were	 included	 in	 the	 ITT	 and	 safety	 populations	 since	
they	were	randomised	and	received	at	least	one	dose	of	study	treat‐
ment.	Seventy‐eight	infants	were	included	in	the	PP	population	(40	










Baseline	 demographic	 and	 anamnestic	 features	 were	 similar	
comparing	 the	 two	 study	 groups	 (Table	 1).	 All	 infants	 were	 from	


















The	 mean	 daily	 duration	 of	 crying	 episodes	 was	 consistently	
shorter	in	the	BB‐12	group	at	each	week	and	decreased	from	week	
to	week	in	both	the	ITT	and	PP	population.	Mean	change	from	base‐






in	 the	BB‐12	group:	−4.7	±	3.4	 (range:	−16.1	 to	0.4)	 vs	−2.3	±	2.2	
(range:	−7.0	to	1.1)	in	placebo	group	(P	=	0.001)	(Figure	2,	panel	2).
The	sleeping	time	increased	from	baseline,	with	a	mean	change	

















BB‐12	 group	 was	 observed	 in	 mean	 daily	 crying	 duration	 starting	
from	V2	and	in	mean	number	of	daily	crying	episodes	from	V3.
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butyrate	 levels	only	 in	32	subjects	 treated	with	BB‐12	and	 in	30	
infants	who	received	the	placebo.	In	Figure	3	panel	1	shows	fae‐












2	 as	 responders	 to	 the	 treatment,	 since	 they	 showed	 a	 signifi‐
cantly higher reduction of crying and calprotectin compared with 
subjects	in	Cluster	1,	associated	with	a	higher	increase	in	HBD‐2,	
LL‐37,	sIgA	and	butyrate	faecal	levels	(P	<	0.05;	Figure	3,	panel	3).
Due	 to	 the	 limited	 amount	 of	 faecal	 sample	 collected	 by	 the	
parents,	gut	microbiota	structure	was	investigated	only	in	a	subset	
of	 the	 infants	 (23	 subjects	 in	 BB‐12	 group	 and	 10	 in	 the	 placebo	
group).	The	overall	gut	microbiota	structure	remained	unchanged	in	
infants	enrolled	in	the	BB‐12	or	in	the	placebo	group.	No	difference	
in	 alpha‐diversity	 index	was	 observed	 upon	 treatment	 (P	 >	 0.05).	







The	 results	 of	 this	 trial	 suggest	 that	 the	 probiotic	Bifidobacterium 
animalis	 subsp.	 lactis	 BB‐12	 is	 effective	 in	 the	 treatment	 of	 IC.	
Administration	of	BB‐12	at	a	daily	dose	of	1	×	109	CFU	was	associ‐













The	study	has	several	 strengths.	Main	strengths	are	 the	 ran‐
domised,	double	blind,	placebo‐controlled	design,	the	use	of	val‐
idated	 procedure	 for	 IC	 diagnosis	 and	 the	 use	 of	 a	well‐defined	
probiotic	strain	with	a	well	characterised	genome	sequence.7 The 




Group	 for	 Probiotics	 and	 Prebiotics.28 The concomitant evalua‐
tion	of	immunity	and	inflammation	biomarkers,	and	of	gut	micro‐
biota	 structure	 and	 butyrate	 production	 could	 be	 relevant,	 also	
in	 helping	 our	 knowledge	on	 the	 probiotics	 action	 in	 IC.	 Infants	
treated	with	BB‐12	showed	a	higher	increase	of	all	immunity	bio‐
markers	 (HBD‐2,	LL‐37	and	of	sIgA)	compared	to	subjects	 in	 the	
placebo	group,	suggesting	that	this	probiotic	strain	is	able	to	exert	
an	 immunomodulatory	 action	 in	 the	 infant	 gut.	 These	 data	 are	
well	in	line	with	previous	findings	showing	that	BB‐12	modulates	
proliferation	 of	 human	 peripheral	 blood	 mononuclear	 cells	 and	
cytokines	 expression,29,30	with	 protective	 action	 against	 gastro‐
intestinal	 infections	 in	 infants	and	children.	 In	 the	context	of	 IC,	
these	effects	could	be	responsible	for	a	beneficial	shaping	of	gut	
microbiota	structure.	 It	 is	well‐known	that	a	positive	modulation	
of	 HBD‐2,	 LL‐37	 and	 sIgA	 expressions	 into	 the	 intestinal	 lumen	
results	 in	 a	 positive	 influence	 on	 gut	 microbiota	 structure	 and	
butyrate production.15	 These	 effects	 seem	 particularly	 relevant	
in	 IC,	where	dysbiosis	with	 increased	presence	of	Proteobacteria 
and	 decreased	 presence	 of	Bifidobacteria with reduced butyrate 
production	 have	 been	 demonstrated.31,32	 A	 pathogenetic	mech‐





increase	 and	 facilitating	 the	 Bifidobacteria	 increase	 and	 butyr‐
ate	production	 in	 infant	with	colic.	These	effects	were	observed	
in	 the	 vast	majority	 but	 not	 in	 all	 infants	 enrolled	 in	 the	 BB‐12	
group,	 supporting	 the	 hypothesis	 that	 other	 factors	 could	 influ‐
ence	these	effects.	The	beneficial	role	of	Bifidobacteria	in	IC	was	
also	demonstrated	by	 the	 significant	 correlation	with	 the	 reduc‐
tion	of	crying	time	observed	in	this	trial.	Bifidobacteria are not able 
to	produce	butyrate,	but	through	cross‐feeding	other	commensal	





axis,	and	exerts	a	potent	anti‐inflammatory	action.35‐46 The faecal 
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calprotectin could be involved in the modulation of the gut inflam‐
matory	state	elicited	by	this	probiotic.
Finally,	 it	 is	well‐known	that	butyrate	modulates	HBD‐2,	LL‐37	
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